Regeneron Pharmaceuticals Inc (WBO:REGN)
€ 856 -1.6 (-0.19%) Market Cap: 94.01 Bil Enterprise Value: 87.45 Bil PE Ratio: 24.44 PB Ratio: 3.60 GF Score: 96/100

Regeneron Pharmaceuticals Inc to Provide Updates on the Company's Oncology Portfolio Call at ASCO Transcript

Jun 07, 2021 / 08:30PM GMT
Release Date Price: €423.9 (-0.08%)
Operator

Good day, and thank you for standing by. Welcome to the Regeneron Investor Event ASCO 2021 Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Justin Holko, Vice President of Investor Relations. Please go ahead.

Justin Holko
Regeneron Pharmaceuticals, Inc. - VP of IR

Thank you, Gigi. Welcome, everyone, to Regeneron's Oncology Investor Webcast. Joining me on the call today are Dr. George Yancopoulos, Co-Founder, President and Chief Scientific Officer; Dr. David Weinreich, Executive Vice President and Head of Clinical Development; Dr. Andres Sirulnik, Senior Vice President, Translational and Clinical Sciences, Hematology; Dr. Israel Lowy, Senior Vice President of Translational Sciences and Oncology; and Marion McCourt, Executive Vice President and Head of Commercial. After our prepared remarks, we will open the call for Q&A.

Before handing the call over to George, I'd like to remind you that remarks made today

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot